NURIX THERAPEUTICS, INC.
Equity & Debt
| Period | Long Term Debt | Share Holder Equity | Cash on Hand |
|---|---|---|---|
| Nov 2018 | — | $-36.8M | $25.6M |
| Feb 2019 | — | $-39.4M | — |
| May 2019 | — | $-42.2M | — |
| Aug 2019 | — | $-44.4M | $51.8M |
| Nov 2019 | — | $-57.7M | $34.8M |
| Feb 2020 | — | $-69.8M | $56.4M |
| May 2020 | — | $-61.5M | $159.3M |
| Aug 2020 | — | $307.6M | $265.5M |
| Nov 2020 | — | $290.3M | $119.4M |
| Feb 2021 | — | $270.1M | $126.4M |
| May 2021 | — | $398.2M | $188.2M |
| Aug 2021 | — | $375.2M | $147.4M |
| Nov 2021 | — | $342.3M | $80.5M |
| Feb 2022 | — | $305.9M | $78.8M |
| May 2022 | — | $266.7M | $41.5M |
| Aug 2022 | — | $342.5M | $47.6M |
| Nov 2022 | — | $303.7M | $64.5M |
| Feb 2023 | — | $274.1M | $33.6M |
| May 2023 | — | $259.9M | $59.0M |
| Aug 2023 | — | $233.8M | $42.3M |
| Nov 2023 | — | $200.5M | $54.6M |
| Feb 2024 | — | $168.7M | $49.8M |
| May 2024 | — | $370.7M | $116.8M |
| Aug 2024 | — | $376.9M | $99.0M |
| Nov 2024 | — | $527.0M | $110.0M |
| Feb 2025 | — | $480.9M | $75.9M |
| May 2025 | — | $447.6M | $84.3M |
| Aug 2025 | — | $372.3M | $78.4M |
| Nov 2025 | — | $538.7M | $247.0M |
| Feb 2026 | — | $480.9M | $71.2M |
| May 2026 | — | $402.6M | $67.7M |